Indobufen is a platelet aggregation inhibitor and a reversible cyclooxygenase inhibitor. It has been used in studying the supportive care and prevention of Atrial Fibrillation.
Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes. Indobufen prevents TF expression and activity both in isolated and in whole blood monocytes. Reduction of TxA2 synthesis, coupled with a lack of effect on PGE2 levels and prevention of ERK1/2 phosphorylation are highlighted as the mechanisms through which indobufen negatively affects TF[1]. Intragastric-administrated indobufen can significantly reduce the APTT (activated partial thromboplastin time), PT (prothrombin time), TT (thrombin time), PF3 (platelet factor 3,4), FI, II, V, VIII, and X (the coagulation factor 1, 2, 5, 8, 10) plasma contents. Its inhibitory effect on plasma FII was better than thrombin inhibitor dabigatran with effect on FX better than FXa inhibitor rivaroxaban[2]. Indobufen has been shown to be as effective as aspirin plus dipyridamole in preventing the reocclusion of coronary and femoro-popliteal artery bypass grafts and has been shown to significantly reduce platelet deposition on haemodialysis membranes[3].
搜索
